Rethymic Implant
Product Images NDC 72359-001

7 FDA label images from Sumitomo Pharma America, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Rethymic (NDC 72359-001). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sumitomo Pharma America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Ret03 0002 01)

Figure 1 (Ret03 0002 01)
An instructional illustration depicting the preparation of a RETHYMIC implant. It shows a sequence where a tool or instrument is being used to handle circular thymus tissue implants, indicating steps involved in their manipulation prior to intramuscular implantation.*
FDA Label Image

Figure 2 (Ret03 0002 02)

Figure 2 (Ret03 0002 02)
An anatomical illustration showing the process of intramuscular implantation of the RETHYMIC implant into the upper arm muscle. The diagram highlights the arm with a dashed outline indicating the implant path and arrows pointing to the muscle site for placement.*
FDA Label Image

Figure 3 (Ret03 0002 03)

Figure 3 (Ret03 0002 03)
An instructional illustration showing a close-up of an implant being inserted intramuscularly, depicting the tissue and the implant placement process. The image visually supports the procedure related to the use of the RETHYMIC implant.*
FDA Label Image

Figure 4 (Ret03 0002 04)

Figure 4 (Ret03 0002 04)
An anatomical illustration showing a cross-section of a muscle with fibers and a 1 cm scale bar. This diagram may relate to the administration site or placement of RETHYMIC implant for intramuscular use.*
FDA Label Image

Figure 5 (Ret03 0002 05)

Figure 5 (Ret03 0002 05)
A clinical trial survival curve graph for RETHYMIC implant showing Kaplan-Meier estimates of event-free survival over 25 years. The graph compares the RETHYMIC clinical trial participants and a natural history population, with a time scale in years on the x-axis and event-free survival probability on the y-axis.*
FDA Label Image

Principal Display Panel (22,000 mm Container Label)

Principal Display Panel (22,000 mm Container Label)
Text panel for RETHYMIC allogeneic processed thymus tissue implant describing dosage (22,000 mm²), handling instructions, formulation details, storage conditions, lot number, expiration date, container count, contents, intended use for surgical implantation, manufacturer information, and contact details.*
FDA Label Image

Principal Display Panel (22,000 mm Container Box Label)

Principal Display Panel (22,000 mm Container Box Label)
Label for RETHYMIC allogenic processed thymus tissue - agdc implant. The label specifies dosage for the entire lot as 5,000 to 22,000 mm^2 of RETHYMIC per recipient body surface area with the entire lot containing 22,000 mm^2. The product is formulated in media supplemented with fetal bovine serum, preservative free, and requires aseptic handling. Storage instructions indicate room temperature with no freezing or refrigeration. Manufactured for Sumitomo Pharma America, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.